PuSH - Publication Server of Helmholtz Zentrum München: IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Sheng, X.* ; Nenseth, H.Z.* ; Qu, S.* ; Kuzu, O.F.* ; Frahnow, T. ; Simon, L. ; Greene, S.* ; Zeng, Q.* ; Fazli, L.* ; Rennie, P.S.* ; Mills, I.G.* ; Danielsen, H.* ; Theis, F.J. ; Patterson, J.B.* ; Jin, Y.* ; Saatcioglu, F.*

IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Nat. Commun. 10:323 (2019)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Activation of endoplasmic reticulum (ER) stress/the unfolded protein response (UPR) has been linked to cancer, but the molecular mechanisms are poorly understood and there is a paucity of reagents to translate this for cancer therapy. Here, we report that an IRE1 alpha RNase-specific inhibitor, MKC8866, strongly inhibits prostate cancer (PCa) tumor growth as monotherapy in multiple preclinical models in mice and shows synergistic antitumor effects with current PCa drugs. Interestingly, global transcriptomic analysis reveal that IRE1 alpha-XBP1s pathway activity is required for c-MYC signaling, one of the most highly activated oncogenic pathways in PCa. XBP1s is necessary for optimal c-MYC mRNA and protein expression, establishing, for the first time, a direct link between UPR and oncogene activation. In addition, an XBP1-specific gene expression signature is strongly associated with PCa prognosis. Our data establish IRE1 alpha-XBP1s signaling as a central pathway in PCa and indicate that its targeting may offer novel treatment strategies.

Altmetric

Additional Metrics?

[➜Log in]